Form 4: iRhythm CAO Marc Rosenbaum's RSU Vesting & Tax Sale

iRhythm Holdings' Chief Accounting Officer, Marc Rosenbaum, acquired 9,210 shares from RSU vesting and subsequently sold 4,797 shares for tax obligations.

Summary

• Marc Rosenbaum, Chief Accounting Officer of iRhythm Holdings, Inc. (IRTC), acquired 9,210 shares of common stock on February 24, 2026.
• This acquisition resulted from the vesting of performance Restricted Stock Units (RSUs) granted on August 11, 2023, after the Compensation & Human Capital Management Committee determined that performance conditions were met.
• Following the acquisition, Rosenbaum's beneficial ownership increased to 19,811 shares.
• On February 25, 2026, Rosenbaum sold 4,797 shares of common stock at a price of $135.4189 per share.
• The sale was conducted to cover tax withholding and remittance obligations associated with the vesting of the performance RSUs.
• After these transactions, Rosenbaum's beneficial ownership stands at 15,014 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of performance RSUs is a positive signal regarding past performance, while the subsequent tax-related sale is a routine administrative action.

Positives

• The vesting of 9,210 performance RSUs indicates that the Compensation & Human Capital Management Committee determined that performance conditions were met, suggesting positive company performance or achievement of specific goals.
• Marc Rosenbaum retains a significant beneficial ownership of 15,014 shares after the transactions, aligning his interests with shareholders.

Negatives

• The sale of 4,797 shares, even if for tax purposes, reduces the direct equity holding of a key executive.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent sales for tax purposes are standard practices for executive compensation in the healthcare technology sector, reflecting the achievement of pre-defined performance milestones. This type of transaction is common across publicly traded companies as a mechanism for executives to realize value from their equity awards while managing tax liabilities.

Comparison to Industry Standards

• The structure of performance-based RSU grants is a common practice among peer companies in the medical device and digital health industry, such as Dexcom (DXCM) or Insulet (PODD), aligning executive incentives with long-term company performance.
• The sale of shares to cover tax obligations upon RSU vesting is a standard and expected event for executives across all industries, including technology and healthcare, and is not indicative of a lack of confidence in the company.

Stakeholder Impact

• Shareholders: The vesting of performance RSUs suggests that the company met certain performance targets, which could be viewed positively by shareholders. The executive's continued significant ownership aligns interests.
• Employees: The compensation structure involving performance RSUs can serve as a model for other employees, linking rewards to company performance.

Key Dates

Recommendation

This Form 4 details routine executive compensation events (RSU vesting and tax-related share sale) and does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal a significant positive or negative shift in the company's outlook.

Keywords

iRhythm Holdings, IRTC, Marc Rosenbaum, Chief Accounting Officer, Form 4, Insider Transaction, RSU Vesting, Stock Sale, Equity Compensation, Performance Shares, Tax Withholding